Influenza vaccine GSK1562902A Formulation 1 — Competitive Intelligence Brief

Influenza vaccine GSK1562902A Formulation 1 (Influenza vaccine GSK1562902A Formulation 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology.

phase 3 Influenza vaccine Immunology Biologic

Target snapshot

Influenza vaccine GSK1562902A Formulation 1 (Influenza vaccine GSK1562902A Formulation 1) — GlaxoSmithKline. This vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Influenza vaccine GSK1562902A Formulation 1 TARGET	Influenza vaccine GSK1562902A Formulation 1	GlaxoSmithKline	phase 3	Influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
Trivalent split Inf	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
inactivated split-virus influenza vaccine	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
VaxigripTetra™ by Sanofi, Inc.	VaxigripTetra™ by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Inactivated quadrivalent influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class